Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab AI vs APFS PK Study in Healthy Volunteers
NCT05339100Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of anifrolumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under serum concentration-time curve from time zero extrapolated to infinity, Area under serum concentration-time curve from time zero to last quantifiable concentration and 1 more. Started Mar 2022; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05339100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339100.